We're developing new and existing drugs for inhalational therapy of mycobacterial disease. Our focus is on a novel approach to treat drug-resistant organisms, ensuring safety and efficacy using dry powders. The initial preclinical testing of dry powder inhaler products typically occurs in a murine model prior to movement to a larger animal model.

A significant limitation to this approach is the lack of suitable device technology for accurate and reproducible delivery of dry powders to small animals. The disposable dosators that we have developed are easy to manufacture, making them accessible and cost-effective for initial proof-of-concept studies in mice. The disposable nature allows their use in animal procedure rooms without concerns for cleaning, refilling, and weighing out materials for reusable devices.

Our future work will employ biotherapeutic moieties targeted to the pathogen that will avoid any effects on the host. This approach then can be tailored to the patient because it's pathogen specific.